MolMed

MolMed was a clinical stage biotechnology company focused on research, development, manufacturing, and clinical validation of innovative therapies, including gene and cell therapies for the treatment of cancer and rare diseases. The company was one of the first in Europe to have obtained the GMP manufacturing authorization for cell and gene therapies ex vivo for both the company's proprietary products and for third-party products. MolMed worked on its own products and worked as a contracted manufacturer for companies developing gene and cell therapy products.

MolMed's proprietary product, Zalmoxis, was a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors to help patients with high-risk hematological malignancies in order to reduce or completely eliminate post-transplant immunosuppression prophylaxis and inducing immune reconstitution. MolMed was also developing a therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic.

In July 2020, MolMed was acquired by AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO). As MolMed was a listed company at the time, AGC acquired the company through a tender offer for the shares of the company, completed in September 2020, at which point MolMed was delisted from the Milan Stock Exchange and became a part of AGC Biologics. The acquisition of MolMed allowed AGC Biologics to offer end-to-end cell and gene therapy CDMO services.